# Targeting VEGF-Sustaining Signaling to Restore Homeostasis in the Outer Retina



#### M. Elizabeth Hartnett

Calvin S. and JeNeal N. Hatch Presidential Endowed Chair Distinguished Professor of Ophthalmology and Visual Sciences Haibo Wang, Aniket Ramshekar, Eric Kunz Moran Eye <u>Center, University of Utah</u>

### **Financial Disclosure**

- Discuss anti-VEGF agents in relationship to clinical trials
- Financial interests or relationships:
  - Knights Templar Eye Foundation: Consultant/Advisor
  - Lippincott Williams and Wilkins: Royalty
  - NIH/NEI: Grant Support
  - Novartis: Grant Support; PAREXEL: Grant Support
- US patent # 10,214,741 (2/26/2019)

### Summary

- AMD influenced by genetic predisposition and external stresses that affect outer retina photoreceptors, RPE and choroid
- Activation of Rac1 by VEGF and other AMD stresses necessary for choroidal endothelial cell migration across RPE, a key step for type 2 MNV
- Sustained activation of Rac1 involves binding to adaptor protein, IQGAP1
- Targeting the Rac1/IQGAP1 binding site reduces sustained Rac1 activation and might safely restore homeostasis despite multiple stresses that cause pathology in AMD

### Background

- Anti-VEGF agents effective in neovascular AMD
- But improve vision in about 50% of patients
- We focused on effector of VEGF Rac1GTP
  - activated by other known stresses associated with AMD oxidation and inflammation
  - and is necessary for activating choroidal endothelial cells to migrate across the RPE, important step in type 2 macular neovascularization (MNV)



### Rac1

- Besides Rac1GTP's effects on choroidal endothelial cell migration across the RPE
- Rac1GTP
  - subunit for NADPH oxidase, a key enzyme generating ROS
    - for intracellular signaling of NFkB and inflammatory pathways
    - for defense against microbes
- Instead of targeting Rac1, which can have beneficial effects fighting infection, we explored an adaptor protein that binds Rac1GTP in cancer and disease

### **IQGAP1**

- IQ protein motif containing GTPase activating protein 1 (IQGAP1) – multiple domains bind different signaling effectors
- Inactive in cytoplasm when not bound
- When bound, coordinates intracellular signaling to enable biologic events
  - Nuclear transcriptional events
  - Altering cell shape for migration
  - Interacting with ECM at cell membrane

## Hypothesis

• IQGAP1 was important in Rac1GTP (active Rac1) mediated choroidal neovascularization

 Rac1GTP binding to IQGAP1 domain sustained its activation induced by VEGF

### Methods

- *Iqgap1<sup>-/-</sup>* and littermate *Iqgap1<sup>+/+</sup>* mice lasered and 7 days later:
  - Assayed for choroidal neovascularization (CNV; lectin-stained)
  - Immunohistochemistry for IQGAP1 and Rac1GTP
- Human choroidal endothelial cells (CECs) from adult donor eyes:
  - Transfected with Iqgap1 or control siRNA, treated with VEGF or PBS
  - Transfected with mutant construct to Rac1 binding domain of IQGAP1 (GFP-IQ-MK24) or control (GFP-IQ-WT), time course of VEGF treatment or PBS
  - Outcomes for both Rac1GTP and Rac1GTP/IQGAP1

### IQGAP1 localized in Human MNV and Experimental CNV



IQGAP1 localized with lectin-labeled CNV 7 days after laser C57bl6/J mice

Sections human neovascular AMD and MNV, courtesy of Hans Grossniklaus, Emory



#### Iqgap1<sup>-/-</sup> had less CNV than littermate controls and Less Colocalization with Rac1GTP in CNV



#### IQGAP1 Knockdown inhibited VEGF induced VEGFR2 activation, Rac1GTP and Rac1GTP binding IQGAP1



Control siRNA IQGAP1siRNA









### IQGAP1 Knockdown Inhibited VEGF-induced CEC Migration



#### VEGF Induced Sustained Rac1GTP over 2 hours when Bound to IQGAP1



### Conclusions

• Sustained activation of Rac1 by VEGF involves binding the adaptor protein, IQGAP1

- Targeting the IQGAP1 binding site of Rac1GTP reduces the time course of Rac1 activation and may be a method to restore homeostasis
  - despite multiple stresses that cause pathology in AMD
  - without removing beneficial aspects of active Rac1

#### Acknowledgements NIH/NEI

- R01 EY015130
- R01 EY017011
- T35 EY026511
- R13 EY029900
- NEI PEDIG ROP1 study
- T32 EY024234 (AR)

Departmental Research to Prevent Blindness Retina Research Foundation, Paul Kayser PAAO Calvin S. & JeNeal N. Hatch Presidential Endowed Chair



#### Hartnett Lab

Haibo Wang **Colin Bretz** Lauren Flom Eric Kunz Aniket Ramshekar Mark Albrecht Carson Kennedy Silke Becker **Steve Budd** Pete Geisen Manabu McCloskey Janet McColm Kassem Hajj **Grace Byfield Yanchao Jiang** Ivan Cardenas Aaron Simmons Collaborators Chris Hill, Utah David Sacks, NIH Brahim Chaqour, Downstate Bill Hauswirth, U of Florida